Pharma Stocks Insights from the Latest Nomura Report
Pharma Stocks Report Overview
Pharma stocks have been notably impacted, with the latest Nomura report revealing that Indian pharmaceutical giants are experiencing a halt in new drug applications. With new filings at their lowest in the past 19 years, the report suggests this is a strategic choice for quality over quantity. The report indicates a decline in ANDA filings from 567 to 521 between Oct-23 and Jun-24, with complex filings contributing significantly to this trend.
Lupin's Performance in the Spotlight
Lupin is highlighted as the only buying recommendation within the report, preparing to launch PredForte, potentially capturing a market of $200 million with significant exclusivity. However, the report also notes setbacks for the company, especially regarding market share in drugs like Suprep and Albuterol.
Comparative Analysis of Other Key Players
- Sun Pharma: Growth in the specialty segment is slowing, with sales of Ilumya declining recently.
- Cipla and Zydus Lifesciences: Both companies continue to show growth despite ongoing regulatory concerns and market competition.
In response to this dynamic environment, Nomura's insights serve as a crucial guide for investors observing the evolving landscape of pharma stocks.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.